Find clinical trials | Bayside Health (Alfred)

77242113PSO3001

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis (NCT06095115)

No longer recruiting

77242113PSO3004

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (NCT06220604)

No longer recruiting

ADR

Australasian Dermatology Registry (Trial Not Registered)

The Australasian Dermatology Registry captures real world data to enable monitoring and surveillance of current and emerging treatments and provides a platform for dermatology research, helping dermatologists provide the best care to their patients. The Australasian Dermatology Registry is a national collaboration between dermatologists, facilitated and coordinated by the Skin Health Institute.

Currently recruiting

Amgen 20230053

A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies (NCT06527404)

No longer recruiting

Aqua EFC17599

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis [AD] who are on background topical corticosteroids and have had an inadequate response to prior biologic therapy or oral Janus Kinase [JAK] inhibitor treatment (NCT06241118)

Currently recruiting

Bi 1368-0140

A multi-centre, randomised, placebo-controlled, doubleblind, parallel-group trial to evaluate safety and efficacy of spesolimab [BI 655130] in adult patients with ulcerative pyoderma gangrenosum [PG] who require systemic therapy (NCT06624670)

The 1368-0140 study is designed to evaluate the safety and efficacy of Spesolimab in adult participants with ulcerative pyoderma gangrenosum (PG) who require systemic therapy.
The treatment period will be approximately 52 weeks and will be administered monthly via infusion.

Currently recruiting

Celldex CDX0159-13

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment [EMBARQ – CSU2] (NCT06455202)

The CDX0159-13 study is designed to evaluate the safety and efficacy of Barzolvolimab in adult participants with chronic spontaneous urticaria (CSU) who still have symptoms despite H1-antihistamine treatment. Participants receive either trial medication or a placebo (something that looks like the trial drug but has no effect on the body), both administered as injections under the skin (subcutaneous). The treatment period will be approximately 52 weeks with all participants moved to active treatment (receiving treatment drug) after Week 24.

No longer recruiting

CGIA632B12201 VITESS

A multicenter, randomized, double-blind, placebo-controlled, dose-range Phase II study to assess the efficacy and safety of GIA632 in patients with non-segmental vitiligo not adequately controlled with topical therapies [GIA632B12201 Vitiligo]. (NCT07431177)

This trial is investigating the safety and efficacy of GIA632 in adults with non-segmental vitiligo vs placebo. This trial lasts approximately one year and ongoing treatment is available for eligible participants. GIA632 is given via a subcut injection (injection into the stomach tissue) at fortnightly intervals.

Currently recruiting

CLOU064J12301

A randomized, double-blind, double-dummy, placebocontrolled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis suppurativa (NCT06799000)

No longer recruiting

CLOU064M12301

A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines (NCT05976243)

No longer recruiting

Dren Bio DR-0201-AIM-001

A Phase 1, Open-label, Multiple Ascending Dose Basket Study to Evaluate the Safety and Activity of DR-0201 in Patients with Select Autoimmune Rheumatic Diseases (NCT06647069)

The DR-0201-AIM-001 study is designed to evaluate the safety and efficacy of DR-0201 in adult participants with lupus, primary Sjögren’s syndrome and/or scleroderma.
Participants receive trial medication via an infusion over 26 weeks at varying intervals.

Currently recruiting

EFC17600

A Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, parallel group 48-week extension study to evaluate the treatment response and safety of two amlitelimab dose regimens administered as monotherapy by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis (NCT06407934)

No longer recruiting

INCB 054707-306 STOP-PN2

Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis [STOP-PN2] (NCT06516965)

This study is designed to evaluate the effect of povorcitinib on itch and skin lesions in participants with Prurigo Nodularis. Participants receive either trial medication or a placebo (something that looks like the trial drug but has no effect on the body), both taken orally. The treatment period will approximately be 13 months including safety follow up.

No longer recruiting

Lavender D346BC00001

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus who are Refractory and/or Intolerant to Antimalarial Therapy (NCT06015737)

The D346BC00001 study is designed to evaluate the efficacy and safety of anifrolumab in adults with chronic and/or subacute lupus erythematous.
Participants receive either trial medication or a placebo (something that looks like the trial drug but has no effect on the body), both administered weekly as injections into the skin (subcutaneous injections). The treatment period will be approximately 52 weeks with all participants moving to active treatment (receiving treatment drug) after Week 24.

Currently recruiting

LTS17367 RIVER-AD

A long-term extension study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in participants of previous amlitelimab clinical trials in moderate to severe atopic dermatitis (NCT05492578)

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atopic dermatitis (AD). The main objective of this study is to evaluate if those participants who received amlitelimab dose 1 in the parent studies (EFC17559 [COAST-1], EFC17560 [COAST 2], EFC17561 [SHORE]) and were responders can maintain their response either remaining at dose 1 or switching to dose 2 of amlitelimab compared to treatment withdrawal.

Currently recruiting

M23-698

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (NCT05889182)

The M23-698 trial is a study designed to evaluate the safety and efficacy of a potential new medication compared to placebo in reducing symptoms and improving the quality of life for participants living with Hidradenitis Supparativa (HS). Participants receive either trial medication or a placebo (something that looks like the trial drug but has no effect on the body), both administered as oral treatments. The study will involve 19 study visits over the course of approximately two years.

Currently recruiting

MK7240-012

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderate to Severe Hidradenitis Suppurativa (NCT06956235)

This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. This study consists of a 16-week Double-blind Period and a 100-week Longterm Extension (LTE) composed of a 40-week Main Extension and a 60-week Optional Extension. Each participant will participate in the study for approximately 135 weeks from the time the participant provides documented informed consent through the final contact. (including screening & follow up). There will be 147 participants across 70 centers worldwide.

No longer recruiting

Pfizer B7981080

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBOCONTROLLED MULTI-CENTER STUDY WITH A DOUBLE-BLIND 52-WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UP/DOSE DOWN TITRATION INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO (NCT06072183)

No longer recruiting

Rainbow Trial [RAY902CT]

PHASE IB OPEN LABEL BASKET TRIAL OF RAY121 TO INHIBIT CLASSICAL COMPLEMENT PATHWAY IN IMMUNOLOGICAL DISEASES [RAINBOW TRIAL] (NCT06371417)

The RAY902CT study is designed to evaluate the safety and efficacy of RAY121 in adult participants with Bullous Pemphigoid (BP) or Behcet’s syndrome. Participants receive trial medication via a monthly injection under the skin (subcutaneous). The treatment period will be approximately 12 weeks with the option of a long-term extension.

Currently recruiting

ROCKET-ASCEND

A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) (NCT05882877)

No longer recruiting